MIKA KAKEFUDA DERYNCK, M.D.
Medical Practice at Hilltop Rd, San Mateo, CA
License number
California GO79889
Category
Medical Practice
Type
Specialist
Address
Address
27 Hilltop Rd, San Mateo, CA 94402
Phone
(415) 999-3933
Professional information
Extending Time To Disease Progression Or Survival In Cancer Patients
US Patent:
2006018, Aug 24, 2006
Filed:
Feb 21, 2006
Appl. No.:
11/359185
Inventors:
Mika Derynck - San Mateo CA, US
Stephen Kelsey - Montara CA, US
Stephen Kelsey - Montara CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395
US Classification:
424155100
Abstract:
The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
Methods Of Treating Mesothelioma With A Pi3K Inhibitor Compound
US Patent:
2012030, Dec 6, 2012
Filed:
Jun 1, 2012
Appl. No.:
13/486141
Inventors:
Mika K. Derynck - San Mateo CA, US
Jennifer O'Hara Lauchle - Larkspur CA, US
Jennifer O'Hara Lauchle - Larkspur CA, US
International Classification:
A61K 31/5377, A61K 31/7068, A61K 33/24, A61P 35/00, A61K 39/395
US Classification:
4241331, 5142342, 424649, 514 49
Abstract:
Methods are provided for treating mesothelioma patients with a dual PI3K/mTOR inhibitor, GDC-0980: (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin--yl)-2-hydroxypropan--one, and having the structure:
Extending Time To Disease Progression Or Survival In Cancer Patients
US Patent:
2011016, Jul 7, 2011
Filed:
Jan 21, 2011
Appl. No.:
13/010985
Inventors:
MIKA K. DERYNCK - San Mateo CA, US
Stephen M. Kelsey - Montara CA, US
Stephen M. Kelsey - Montara CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241331, 4241581
Abstract:
The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
Extending Time To Disease Progression Or Survival In Cancer Patients
US Patent:
2009015, Jun 18, 2009
Filed:
Nov 14, 2008
Appl. No.:
12/271564
Inventors:
Mika K. Derynck - San Mateo CA, US
Stephen M. Kelsey - Montara CA, US
Stephen M. Kelsey - Montara CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241331, 4241581, 4241431
Abstract:
The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.